Breast Cancer Profiling Project, Drug Sensitivity phase I: Fixed-cell GR measures of 35 breast cell lines to 34 small molecule perturbagens from library plate I. Dataset 1 of 2: Normalized growth rate inhibition values - Dataset (ID:20343)

 Full screen view
Filter results: >>>>
Cell Small Molecule Small Mol Concentration (uM) Primary Target Pathway Mean Normalized Growth Rate Inhibition Value Increased Fraction Dead
SK-BR-3 Cediranib
3.1623
VEGFR/cKIT
RTK
 0.9745 -0.00714
SK-BR-3 Cediranib
10.0
VEGFR/cKIT
RTK
 -0.5397 0.49493
SK-BR-3 Cabozantinib
0.001
VEGFR2/MET
RTK
 0.9790 0.00981
SK-BR-3 Cabozantinib
0.0031623
VEGFR2/MET
RTK
 1.0042 -0.00205
SK-BR-3 Cabozantinib
0.01
VEGFR2/MET
RTK
 1.0250 0.01081
SK-BR-3 Cabozantinib
0.031623
VEGFR2/MET
RTK
 1.1303 -0.00991
SK-BR-3 Cabozantinib
0.1
VEGFR2/MET
RTK
 1.1537 -0.00868
SK-BR-3 Cabozantinib
0.31623
VEGFR2/MET
RTK
 1.2300 -0.00894
SK-BR-3 Cabozantinib
1.0
VEGFR2/MET
RTK
 1.1345 -0.00437
SK-BR-3 Cabozantinib
3.1623
VEGFR2/MET
RTK
 1.0876 -0.01113
SK-BR-3 Cabozantinib
10.0
VEGFR2/MET
RTK
 0.4422 0.03459
BT-20 Abemaciclib
0.001
CDK4/6
Cell cycle
 0.9370 -0.00149
BT-20 Abemaciclib
0.0031623
CDK4/6
Cell cycle
 0.8833 -0.00527
BT-20 Abemaciclib
0.01
CDK4/6
Cell cycle
 0.7022 -0.00034
BT-20 Abemaciclib
0.031623
CDK4/6
Cell cycle
 0.4936 -0.00426
BT-20 Abemaciclib
0.1
CDK4/6
Cell cycle
 0.3565 0.00950
BT-20 Abemaciclib
0.31623
CDK4/6
Cell cycle
 0.2635 0.00452
BT-20 Abemaciclib
1.0
CDK4/6
Cell cycle
 0.2233 0.00560
BT-20 Abemaciclib
3.1623
CDK4/6
Cell cycle
 0.1622 0.01068
BT-20 Abemaciclib
10.0
CDK4/6
Cell cycle
 -0.2160 0.37259
BT-20 Palbociclib
0.00031623
CDK4/6
Cell cycle
 1.0619 -0.00163
BT-20 Palbociclib
0.001
CDK4/6
Cell cycle
 1.0987 -0.00539
BT-20 Palbociclib
0.0031623
CDK4/6
Cell cycle
 0.9966 0.00011
BT-20 Palbociclib
0.01
CDK4/6
Cell cycle
 0.8023 0.00566
BT-20 Palbociclib
0.031623
CDK4/6
Cell cycle
 0.5715 0.01511